Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
21 April 2022 - 10:05PM
Business Wire
- Conference Call Scheduled for Tuesday, April
26, 2022 at 4:30 p.m. ET -
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics, today announced
that the company will release full year 2021 financial results on
Tuesday April 26, 2022 after the close of market. Ambrx will host a
corresponding conference call and a live webcast at 1:30 p.m. PT /
4:30 p.m. ET on the same day to discuss the results and provide a
corporate update.
Individuals interested in listening to the conference call may
do so by dialing (844) 200-6205 for domestic callers, or (929)
526-1599 for international callers and reference access code:
9264119; or from the webcast link in the investor relations section
of the company's website at: www.ambrx.com.
A webcast replay of the call will be available beginning April
26, 2022 at 4:30 p.m. PT / 7:30 p.m. ET. The webcast will be
available in the investor relations section on the company's
website for 90 days following the completion of the call.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220421005995/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024